Buscopanvet compositum is commonly used to assist with symptoms related to painful spasms and visceral discomfort in veterinary patients. It is relevant for managing symptoms that interfere with daily comfort and may assist patients with coping more steadily during difficult episodes.

The medication is commonly used to help manage symptomatic discomfort in the gastrointestinal, urinary, and biliary systems.

---

Alleviating Acute Visceral Cramping and Spasm

This area addresses symptoms related to heightened physiological activity, such as acute spasms or cramping, especially in the gastrointestinal tract (such as equine colic) and the urogenital system. The medication is commonly used to help with symptom clusters that may become intense or disruptive, providing support that helps ease the overall burden of symptoms associated with severe cramping.

Common indications include spasmodic colics in horses, along with symptoms associated with the gastrointestinal tract, the urinary system, and the bile excretory organs. It is relevant in contexts marked by increased discomfort or tension, supporting the management of intense pain and severe cramping.

“It is applied in addressing symptom clusters where intense visceral pain is accompanied by elevated body temperature (fever).”

---

Managing Intense Pain and Fever in Acute Episodes

The medication is relevant in clinical settings that involve acute or unstable symptom patterns where significant symptoms related to physical discomfort (pain) are present, often combined with fever. It is applied across domains where additional symptomatic support is needed, and may assist with maintaining functional stability and contributing to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Acute Visceral Pain
This combination medicine is commonly used in scenarios requiring short-term symptomatic assistance to manage high-intensity pain and cramping.

Regulatory References

1. Summary of Product Characteristics

Who Can and Cannot Use Buscopanvet compositum?

Eligibility for Buscopanvet compositum is defined by strict regulatory criteria based on the target species, specific comorbidities, and the animal’s food-production status.

---

Populations and Restrictions

Classification	Rule (Official Regulatory Statement)
Eligible Species	Use is formally allowed in Adult Cattle, Horses, and Dogs.
Absolute Contraindications	Must not be used in animals with known hypersensitivity to the active substances or excipients, or in horses suffering from paralytic ileus.
Food Production Prohibitions	Contraindicated for use in cows producing milk for human consumption due to regulatory withdrawal period requirements.
Pregnancy Restriction	Should not be used in pregnant animals as safety during gestation has not been established by regulatory authorities.

---

Eligibility-Related Restrictions

For horses, the product must be administered only via the intravenous route. The intramuscular route is contraindicated due to the risk of local reactions. These classifications establish the boundaries for who is officially eligible for the medicine according to governmental documentation, without providing therapeutic claims or dosing instructions.

Interactions with other medicines and products

This section describes the officially documented interaction patterns of the active components, Hyoscine Butylbromide and Sodium Metamizole, as defined in regulatory information.

Exposure-Altering Interactions

The analgesic component, Sodium Metamizole, may reduce the plasma concentration and systemic exposure of several co-administered medicinal products. This pharmacokinetic effect is attributed to the documented capacity of its metabolite to act as a moderate to strong inducer of specific metabolic enzymes, including CYP3A4, CYP2B6, and CYP2C19. Medicines that may experience this exposure reduction include Ciclosporin (Cyclosporine), Methadone, and Bupropion. This interaction is noted as most relevant when Sodium Metamizole is administered at a high dosage over a period exceeding one day.

Pharmacodynamic and Procedural Constraints

Co-administration with other anticholinergic drugs may result in the potentiation of the anticholinergic effect of Hyoscine Butylbromide. The use of Dopamine antagonists may lead to a diminution of the effects on the gastrointestinal tract. A procedural restriction requires that the intramuscular injection route is prohibited when co-administering with anticoagulant drugs, necessitating the use of the intravenous or subcutaneous routes to mitigate hematoma risk.

Mandatory timing rules exist for certain substances: Acetylsalicylic acid must be administered at least 30 minutes before this medicine, and Antacids or adsorbent antidiarrheals must be given at least one hour before the Hyoscine Butylbromide component. Interactions with food or herbal products are not officially established.

Buscopanvet compositum exerts its effects via two distinct pharmacological components: Scopolamine butylbromide and Metamizole.

Scopolamine butylbromide functions as a competitive muscarinic acetylcholine receptor antagonist, primarily targeting M2 and M3 receptors located on the smooth muscle cells and exocrine glands of the visceral organs, especially the gastrointestinal and urogenital tracts. Its binding blocks the action of the endogenous neurotransmitter acetylcholine. This interruption prevents acetylcholine-mediated Gq protein-coupled receptor signaling, which normally triggers the intracellular cascade involving phospholipase C activation and subsequent increase in inositol trisphosphate (IP3) and diacylglycerol (DAG). The resulting suppression of IP3-mediated release of intracellular calcium (Ca^2+) from the sarcoplasmic reticulum modulates the smooth muscle contractile state, leading to visceral smooth muscle relaxation.

Metamizole acts as a pro-drug, rapidly yielding active metabolites, chiefly 4-methyl-amino-antipyrine (4-MAA). The mechanism of 4-MAA is proposed to involve a dual action: inhibition of cyclooxygenase-3 (COX-3) in the central nervous system, which decreases the synthesis of prostanoids, and activation of central opioidergic and cannabinoid systems. The latter involves the agonistic action of its metabolite on CB1 receptors and engagement of opioid pathways, resulting in modulation of central nociceptive signal transmission. A peripheral mechanism involves the inhibition of prostaglandin E2 (PGE2) synthesis, potentially through the COX pathway or by influencing the TRPV1 receptor, further modulating peripheral pain signaling.

How to Use Buscopanvet compositum

Buscopanvet compositum is a veterinary medicine formulated as a solution for injection, and its use follows specific requirements regarding administration route, dosing, and procedural technique.

---

Administration Route and Species Constraints

This medicine is strictly for parenteral administration, utilizing either intravenous (IV) injection or intramuscular (IM) injection. Critical species-specific constraints apply to the route of delivery.

Species	Approved Administration Route(s)
Horses	Intravenous (IV) Injection Only (IM route is forbidden)
Adult Cattle & Dogs	Intravenous (IV) or Intramuscular (IM) Injection

---

Standard Dosing and Frequency

The required dose is determined by the subject’s body weight to ensure standardized administration. The medicine is typically administered as a single dose for short-term, acute, symptomatic use and is not intended for fixed, long-term, or cyclic regimens.

Species	Standard Dosing Regimen (Volume per Weight)
Horses & Adult Cattle	5 mL per 100 kg body weight
Dogs	0.1 mL per kg body weight

---

Procedural Requirements

Usage requires adherence to specific technical conditions. Aseptic techniques must be employed during administration, and any injection via the intravenous route must be carried out slowly. These procedural instructions define the standardized application of the solution.

Research Evidence / Overview of Studies for Buscopanvet compositum

Evidence from Studies for Equine Colic and Spasm

Research has explored the use of this combination medicine in horses through randomized, controlled field studies where a treatment group receiving the medicine was compared against a group receiving a placebo (an inactive substance). Studies have also been conducted in research settings involving horses with conditions characterized by fluctuating or episodic manifestations, such as various forms of acute abdominal pain or spasm (colic). Researchers primarily used scoring systems to measure outcomes related to physical discomfort, tracking changes in restlessness, agitation, and overall clinical signs over defined, short time intervals. Controlled studies also monitored physiological outcomes, where research examined changes in involuntary muscle contractions within the gastrointestinal tract, including the cecum and colon.

What the studies reported: Findings describe patterns observed in these studies, including measurements taken of discomfort scores when comparing the treated group and the placebo group. Studies monitored and reported measurements of movement in the gut muscles during the observation period. However, some trials focusing on experimental pain models reported measurements of discomfort levels that were not statistically defined when assessing symptom changes. The short follow-up durations were limited, meaning the reported outcomes reflect the findings observed during the time immediately following administration.

---

Controlled Research in Calf Nutritional Diarrhoea

Research evaluating this medicine in calves is primarily derived from controlled studies focusing specifically on conditions associated with acute or disruptive episodes, particularly nutritional diarrhoea. These studies were designed to evaluate the medicine in a highly restricted population. Researchers were interested in outcomes related to systemic or functional imbalance and used objective methods to track changes. For example, studies monitored quantifiable outcomes like daily faecal output, faecal water content, and the consistency of the faeces.

---

Areas of Research Uncertainty and Study Gaps

Based on the available information, there are several areas where certainty remains low or where research is still needed. Follow-up durations were limited in the major clinical trials, which means that there is limited information for long-term outcomes or how the medicine performs over extended periods. For equine use, sample sizes were modest in some experimental studies, and findings were mixed when comparing symptom measurements across different models. The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. FDA Freedom of Information Summary for Buscopan Compositum (NADA 141-198)
2. Summary of Product Characteristics (SPC) for Buscopan Compositum (UK VMD)

Common questions about Buscopanvet compositum (FAQ)

Q: What is Buscopanvet compositum and what is it used for?

Buscopanvet compositum is a veterinary medication used primarily to relieve spasms or colic in horses, cattle, dogs, and cats. It is a combination product that includes hyoscine butylbromide (an antispasmodic) and metamizole (a painkiller/non-steroidal anti-inflammatory drug, or NSAID).

• Hyoscine butylbromide works by relaxing the smooth muscles in the gastrointestinal or urinary tract, which helps to stop painful spasms.
• Metamizole provides pain relief and reduces fever, which is beneficial in conditions associated with painful spasms, such as equine colic.

Q: How is Buscopanvet compositum administered?

Buscopanvet compositum is typically administered by a veterinarian, usually as an intravenous or intramuscular injection. The route and dose are dependent on the species (horse, cattle, dog, or cat), the animal's weight, and the specific condition being treated.

• It is not an over-the-counter or at-home medication for pet owners to administer without professional guidance.
• It is essential that the animal is properly diagnosed by a veterinarian before this medication is used.

Q: What are the main active ingredients in Buscopanvet compositum?

Buscopanvet compositum contains two primary active ingredients:

• Hyoscine butylbromide: This is the antispasmodic component. It works by blocking certain chemical messengers (specifically, acetylcholine at muscarinic receptors) to relax smooth muscles, such as those in the gut.
• Metamizole (also known as Dipyrone): This is the analgesic (pain-relieving) and antipyretic (fever-reducing) component. It belongs to the group of pyrazolone NSAIDs, which acts centrally to relieve pain.

Q: Are there any specific warnings for Buscopanvet compositum?

Yes, there are several warnings, particularly due to the metamizole component. It should not be used in animals with certain pre-existing conditions.

• Gastrointestinal and Hemodynamic Risk: Like other NSAIDs, metamizole can carry risks related to gastrointestinal irritation and changes in blood pressure. Its use should be avoided in animals with a history of gastrointestinal ulcers or significant renal (kidney) or hepatic (liver) impairment.
• Blood Disorders: Metamizole has been linked to blood disorders, such as agranulocytosis, in humans and, less commonly, in animals. Therefore, it is generally contraindicated in animals with existing bone marrow suppression or blood production abnormalities.
• Specific Species: The use of Buscopanvet compositum may be restricted in certain food-producing animals due to regulatory limits, and it is crucial to observe all recommended withdrawal periods for meat and milk consumption after treatment.

Storage and Disposal of Buscopanvet compositum

The storage and disposal of this solution for injection must strictly follow official regulatory requirements to maintain product integrity and safety.

---

Storage and Stability

The product must not be stored above 25 C and must be kept in the outer carton for protection from light. It is mandatory to store the medicine out of the sight and reach of children.

The official shelf life for the product packaged for sale is 3 years. Once the immediate packaging is first opened, the product has a reduced shelf life of 28 days.

---

Disposal

Any unused Buscopanvet compositum or waste materials derived from it must be disposed of in accordance with local requirements established for pharmaceutical waste.